Biomx inc PHGE.US 總覽分析
)PHGE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
PHGE 近期報酬表現
0.86%
Biomx inc
3.56%
同產業平均
1.47%
S&P500
與 PHGE 同產業的標的表現
- RNTX Rein therapeutics inc價值 1 分趨勢 3 分波段 2 分籌碼 1 分股利 1 分查看更多
PHGE 公司資訊
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).